Washington D.C. Political Reporter
SEE OTHER BRANDS

Following politics and government news from Washington, D.C.

RxSight, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) investors of a class action representing investors that bought securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"). RxSight investors have until September 22, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company that develops, manufactures, and sells light adjustable intraocular lenses (“LAL”) used in cataract surgery.

The RxSight class action lawsuit alleges that defendants made false and/or misleading statements and failed to disclose that: (i) RxSight was experiencing adoption challenges and structural issues that were negatively impacting sales and utilization; (ii) demand for RxSight’s products had been overstated; and (iii) as a result, the Company was unlikely to meet its previously issued financial guidance for fiscal year 2025.

The complaint further alleges that on July 8, 2025, RxSight reported preliminary second-quarter 2025 financial results revealing sharp declines in Light Delivery Device (“LDD”) sales, LAL utilization, and overall revenue. RxSight also reduced its full-year 2025 guidance by approximately $42.5 million at the midpoint, while CEO Ronald Kurtz acknowledged that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.” On this news, the price of RxSight stock fell nearly 38%, according to the complaint.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions